An antithrombogenic material includes a coating material containing: a cationic polymer containing, as a constituent monomer, a compound selected from the group consisting of alkyleneimines, vinylamines, allylamines, lysine, protamine, and diallyldimethylammonium chloride; and an anionic compound containing a sulfur atom and having anticoagulant activity; and a base material whose surface is coated with the coating material; wherein the cationic polymer is covalently bound to the base material; the anionic compound containing a sulfur atom and having anticoagulant activity is immobilized on the surface of the base material by ionic bonding to the cationic polymer; and the average thickness of the coating material is 15 to 400 nm.

A sheath introducer facilitates the insertion of a catheter into a peripheral artery. The sheath introducer comprises longitudinally extending exterior and interior surfaces, the interior surface defining a lumen in which blood flow occurs. The sheath introducer exterior surface has a hydrophilic material at least partially coated thereon and at least one biologically active agent disposed on the sheath introducer exterior surface. The at least one biologically active agent can be selected from the group consisting of an anticoagulant agent, an antiplatelet agent, an antiproliferative agent, an antibiotics agent, an anti-inflammatory agent, and an antivasospasmodic agent. In a preferred embodiment, the at least one biologically active agent comprises first, second and third biologically active agents, where the first biologically active agent is an antiproliferative agent, the second biologically active agent is an anticoagulant, and the third biologically active agent is an antivasospasmodic agent.

Endovascular treatment of, for example, delayed cerebral vasospasm involves the placing of a microcatheter in the affected vessels followed by the teachings of the instant disclosure, which is clinically improved with comparison to slow infusion of a vasodilating compound. Systems, processes and self-expanding designed stents and stent-like members are featured and highlighted. The stents and stent-like members being retrieved, nothing is left in the vessel. Drug-eluting stents, resorbable stents and angiographically imageable coatings, including tantalum brushes over part or all of subject system components are also disclosed.

A method for the prophylaxis or treatment of restenosis comprising administering a therapeutically effective amount of Annexin A5 or a functional analog or variant thereof to a patient in need of such treatment. A method for the treatment of stenosis in a patient comprising performing an intervention for the treatment of stenosis in conjunction with administering a therapeutically effective amount of Annexin A5 or a functional analog or variant thereof. A pharmaceutical composition comprising a therapeutically effective amount of Annexin A5 or a functional analog or variant thereof for the prophylaxis or treatment of restenosis. A drug eluting stent, wherein the drug is Annexin A5 or a functional analog or variant thereof, and a method of making such a stent.

The invention provides methods of immobilizing an active agent to a substrate surface, including the steps of, depositing a primer compound on a substrate, thereby forming a primed substrate, contacting the primed substrate with a solution of a compound including a trihydroxyphenyl group, thereby forming a trihydroxyphenyl-treated primed substrate, and contacting the trihydroxyphenyl-treated primed substrate with a solution of an active agent, thereby immobilizing the active agent on the substrate. Further provided are methods of immobilizing an active agent on a substrate, including the steps of providing a substrate, combining a solution of a compound including a trihydroxyphenyl group with a solution of an active agent, thereby forming a solution of an active agent-trihydroxyphenyl conjugate, and contacting the primed substrate with the solution of the active agent-trihydroxyphenyl conjugate, thereby immobilizing the active agent on the substrate. The invention further provides substrates and medical device or device components with active agents immobilized on the surface thereof.

The invention relates to a peptide compound and its pharmaceutical composition for inhibiting platelet aggregation and preventing/treating thrombogenic diseases. The invention develops pentapeptides and hexapeptides derived from snake venom C-type lectin-like proteins (CLPs) fragments, which can inhibit platelet aggregation and have antithrombotic activity without hemorrhagic tendency. Accordingly, they can be used as potential agents for the prevention and therapy of thrombogenic diseases.

A medical device is provided, comprising: an expandable tubular member comprising a plurality of elements forming a sidewall, wherein each of the elements crosses one or more other elements and a plurality of pores are formed among the elements in the sidewall; wherein an antithrombogenic material is coated over the tubular member such that there is inherently no webbing of the antithrombogenic material between any two elements.

The invention relates to a method for producing a bioartificial and primarily acellular fibrin-based construct, wherein a mixture of cell-free compositions containing fibrinogen and thrombin is applied to a surface and subsequently pressurised. An additional aspect of the invention is directed to such fibrin-based bioartificial acellular constructs obtained according to the invention, with improved biomechanical properties, as well as to the use of same in the field of implantology, cartilage replacement or tissue replacement.

The present invention is directed to materials compatible with blood, implantable devices comprising said material, methods of preparation of such material and medical devices coated therewith and uses thereof for anti-thrombotic and/or cell-proliferating aspects.

The present disclosure provides a vascular graft comprising i) one or more extracellular matrix compositions and ii) one or more hydrogels. In particular, the vascular grafts of the present disclosure can be functionalized and/or be completely biologic. The disclosure also provides methods of administering the vascular grafts as well as methods for forming the vascular grafts.